



February 28, 2023

[submitted electronically via: [Albert.Sommers@wyoleg.gov](mailto:Albert.Sommers@wyoleg.gov)]

The Honorable Albert Sommers  
Speaker of the Wyoming House of Representatives  
P.O. Box 1608  
Pinedale, WY 82941

**SF151 (Hutchings) – The Wyoming Prescription Drug Transparency Act – SUPPORT**

Dear Speaker Sommers and members of the Wyoming House of Representatives:

The American Pharmacists Association (APhA) supports [Senate File \(SF\) 151](#) (Senator Hutchings), which will protect Wyoming patients' access to their medications and their trusted healthcare professional, the pharmacist.

APhA is the largest association of pharmacists in the United States advancing the entire pharmacy profession. APhA represents pharmacists in all practice settings, including community pharmacies, hospitals, long-term care facilities, specialty pharmacies, community health centers, physician offices, ambulatory clinics, managed care organizations, hospice settings, and government facilities. Our members strive to improve medication use, advance patient care and enhance public health. In Wyoming, with 530 licensed pharmacists and 590 pharmacy technicians, APhA represents pharmacists, student pharmacists, and pharmacy technicians that practice in numerous settings and provide care to many of your constituents. As the voice of pharmacy, APhA leads the profession and equips members for their role as the medication expert in team-based, patient-centered care. APhA inspires, innovates, and creates opportunities for members and pharmacists worldwide to optimize medication use and health for all.

As a result of the predatory practices of pharmacy benefit managers (PBMs), patients' access to medications from their local pharmacist across the country has declined<sup>1</sup>, taxpayer dollars have been funneled into corporate profits<sup>2</sup>, and generationally owned community pharmacies have been driven out of business<sup>3</sup>. Recently, a study found that PBM tactics forced Oregon Medicaid to overpay \$1.9M on a single drug, where PBMs marked up the drug by 800 percent.<sup>4</sup> Appropriate government intervention is necessary to address

---

<sup>1</sup> Rose J, Krishnamoorth R. Why your neighborhood community pharmacy may close. *The Hill*. Available at <https://thehill.com/blogs/congress-blog/healthcare/530477-why-your-neighborhood-community-pharmacy-may-close>

<sup>2</sup> 3 Axis Advisors. Analysis of PBM Spread Pricing in New York Medicaid Managed Care. Available at <http://www.ncpa.co/pdf/state-advoc/new-york-report.pdf>

<sup>3</sup> Callahan C. Mom-and-pop pharmacies struggle to hang on. *Times Union*. Available at <https://www.timesunion.com/hudsonvalley/news/article/Mom-and-pop-pharmacies-struggle-to-hang-on-16187714.php>

<sup>4</sup> <https://oregonpharmacy.org/2022/10/27/oregon-report/>

the misaligned incentives in the PBM industry that prioritize profits over patients. SF151 would address many of the underlying issues that result in harm to patients, taxpayers, and pharmacists.

An important focus of this legislation is maintaining patients' access to lifesaving medications and preserving the pharmacist-patient relationship. This comes from the prohibition of various PBM activities that increase the costs of medications for patients and can threaten the sustainability of pharmacies. In a February 2023 national survey conducted by APhA, 91.5% of respondents reported that current PBM practices negatively impact their practice and ability to provide patient care.<sup>5</sup> SF151 bans many of these negative practices by prohibiting PBMs charging pharmacies unnecessary fees, spread pricing practices (where a PBM overcharges the plan and underpays the pharmacy), and anti-competitive preferential reimbursements to PBM-owned pharmacies. Additionally, SF151 protects patient autonomy in their healthcare by allowing patients to choose where to fill their prescriptions and prohibits mandating a patient fill their prescriptions by mail which can compromise medication safety.

SF151 takes numerous steps to provide an appropriate level of government oversight into PBM practices that hurt patients and have led to decreased patient access to their medications and local pharmacist.

For these reasons, we support SF151 and respectfully request your "AYE" vote. If you have any questions or require additional information, please don't hesitate to contact E. Michael Murphy, PharmD, MBA, APhA Advisor for State Government Affairs by email at [mmurphy@aphanet.org](mailto:mmurphy@aphanet.org).

Sincerely,

A handwritten signature in black ink, reading "E. M. Murphy". The signature is fluid and cursive, with the first name "E." and last name "Murphy" clearly legible.

E. Michael Murphy, PharmD, MBA  
Advisor for State Government Affairs  
American Pharmacists Association

cc: Members of the Wyoming House of Representatives  
Michael Baxter, APhA Acting Head of Government Affairs

---

<sup>5</sup> Survey of Pharmacists: Quantifying the impact of PBM practices. *American Pharmacists Association*. February 2023.